Form 4: Chimerix VP of Finance and Accounting, David Jakeman, Reports Sale of Shares for Tax Obligations
SEC Form 4 Filing
David Jakeman, VP of Finance and Accounting at Chimerix, sold 300 shares of common stock to cover tax liabilities related to a restricted stock unit award.
Summary
- On February 13, 2025, David Jakeman, the VP of Finance and Accounting at Chimerix Inc. (CMRX), sold 300 shares of common stock.
- The sale was executed at a weighted average price of $4.532 per share, with individual transactions ranging from $4.53 to $4.535.
- The transaction was to cover Jakeman's tax liability incurred upon the vesting of shares from a restricted stock unit award granted on February 1, 2024.
- The sale was conducted under a pre-arranged automatic sell-to-cover arrangement pursuant to Rule 10b5-1.
- Following the transaction, Jakeman directly owns 148,987 shares of Chimerix common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations and doesn't indicate a significant change in the executive's outlook on the company.
Industry Context
This is a routine Form 4 filing, reflecting a common practice of executives selling shares to cover tax obligations related to equity compensation. It doesn't necessarily indicate a change in the executive's confidence in the company.
Comparison to Industry Standards
- Sell-to-cover arrangements are a standard practice among publicly traded companies to facilitate the payment of taxes associated with the vesting of equity awards.
- The filing is consistent with SEC regulations requiring transparency in insider trading activities, similar to filings made by executives at comparable biotech companies like Gilead Sciences or Amgen.
Stakeholder Impact
- The sale of shares has a minimal impact on shareholders as it is a small transaction by an executive to cover tax liabilities.
Key Dates
| Date | Description |
|---|---|
| February 1, 2024 | Date of restricted stock unit award grant. |
| February 13, 2025 | Date of stock sale transaction. |
| February 14, 2025 | Date of Form 4 filing. |
Keywords
Chimerix, CMRX, David Jakeman, Form 4, Insider Trading, Stock Sale, Tax Liability, Restricted Stock Unit, Rule 10b5-1, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.